EP0117345B1 - Aminopyrimidinone als Histamin-H2-Antagonisten - Google Patents
Aminopyrimidinone als Histamin-H2-Antagonisten Download PDFInfo
- Publication number
- EP0117345B1 EP0117345B1 EP83307257A EP83307257A EP0117345B1 EP 0117345 B1 EP0117345 B1 EP 0117345B1 EP 83307257 A EP83307257 A EP 83307257A EP 83307257 A EP83307257 A EP 83307257A EP 0117345 B1 EP0117345 B1 EP 0117345B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- formula
- oxopyridin
- pyrimidin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003485 histamine H2 receptor antagonist Substances 0.000 title claims description 11
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 title 1
- -1 N-substituted pyridone Chemical class 0.000 claims abstract description 111
- 239000001257 hydrogen Substances 0.000 claims abstract description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 25
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 21
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 18
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000005864 Sulphur Substances 0.000 claims abstract description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000001301 oxygen Substances 0.000 claims abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 127
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 81
- 150000003839 salts Chemical class 0.000 claims description 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
- 125000001246 bromo group Chemical group Br* 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims description 10
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 7
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000006308 propyl amino group Chemical group 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- ZUHTVUBHXBVRCR-UHFFFAOYSA-N 5-[(1-benzyl-2-oxopyridin-4-yl)methyl]-2-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethylamino]-1h-pyrimidin-6-one Chemical compound N1C=NC(CSCCNC=2NC(=O)C(CC3=CC(=O)N(CC=4C=CC=CC=4)C=C3)=CN=2)=C1C ZUHTVUBHXBVRCR-UHFFFAOYSA-N 0.000 claims description 4
- UIWHJZCIKYVULI-UHFFFAOYSA-N 5-[[1-[2-(dimethylamino)ethyl]-2-oxopyridin-4-yl]methyl]-2-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethylamino]-1h-pyrimidin-6-one Chemical compound O=C1N(CCN(C)C)C=CC(CC=2C(NC(NCCSCC=3OC(CN(C)C)=CC=3)=NC=2)=O)=C1 UIWHJZCIKYVULI-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 150000003573 thiols Chemical class 0.000 claims description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 3
- XPXIWRWFRGFJQN-UHFFFAOYSA-N 2-[4-[2-[[5-[(1-butyl-2-oxopyridin-4-yl)methyl]-6-oxo-1h-pyrimidin-2-yl]amino]ethylsulfanylmethyl]-1,3-thiazol-2-yl]guanidine Chemical compound O=C1N(CCCC)C=CC(CC=2C(NC(NCCSCC=3N=C(NC(N)=N)SC=3)=NC=2)=O)=C1 XPXIWRWFRGFJQN-UHFFFAOYSA-N 0.000 claims description 3
- BDYPQUYWDVWPIO-UHFFFAOYSA-N 5-[(1-benzyl-2-oxopyridin-4-yl)methyl]-2-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethylamino]-1h-pyrimidin-6-one Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(NC1=O)=NC=C1CC1=CC(=O)N(CC=2C=CC=CC=2)C=C1 BDYPQUYWDVWPIO-UHFFFAOYSA-N 0.000 claims description 3
- WZSGYXGFPMEOPV-UHFFFAOYSA-N 5-[(1-butyl-2-oxopyridin-4-yl)methyl]-2-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethylamino]-1h-pyrimidin-6-one Chemical compound O=C1N(CCCC)C=CC(CC=2C(NC(NCCSCC3=C(NC=N3)C)=NC=2)=O)=C1 WZSGYXGFPMEOPV-UHFFFAOYSA-N 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- IZKFPIRHHXEYFH-UHFFFAOYSA-N 2-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethylamino]-5-[(1-methyl-2-oxopyridin-4-yl)methyl]-1h-pyrimidin-6-one Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(NC1=O)=NC=C1CC1=CC(=O)N(C)C=C1 IZKFPIRHHXEYFH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 48
- 229960001340 histamine Drugs 0.000 abstract description 24
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 3
- 125000002947 alkylene group Chemical group 0.000 abstract description 2
- 239000005557 antagonist Substances 0.000 abstract description 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 230000002829 reductive effect Effects 0.000 description 48
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 37
- 239000011541 reaction mixture Substances 0.000 description 37
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 34
- 239000007787 solid Substances 0.000 description 29
- 239000000203 mixture Substances 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 0 CNC(NC(*)=C1**)=NC1=O Chemical compound CNC(NC(*)=C1**)=NC1=O 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000012362 glacial acetic acid Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- IJLXJSYYINXUOI-UHFFFAOYSA-N n-[5-[(1-butyl-2-oxopyridin-4-yl)methyl]-6-oxo-1h-pyrimidin-2-yl]nitramide Chemical compound O=C1N(CCCC)C=CC(CC=2C(NC(N[N+]([O-])=O)=NC=2)=O)=C1 IJLXJSYYINXUOI-UHFFFAOYSA-N 0.000 description 7
- HWMDMSNFSXOIRK-UHFFFAOYSA-N n-[5-[(1-methyl-2-oxopyridin-4-yl)methyl]-6-oxo-1h-pyrimidin-2-yl]nitramide Chemical compound O=C1N(C)C=CC(CC=2C(NC(N[N+]([O-])=O)=NC=2)=O)=C1 HWMDMSNFSXOIRK-UHFFFAOYSA-N 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- IDCPFAYURAQKDZ-UHFFFAOYSA-N 1-nitroguanidine Chemical compound NC(=N)N[N+]([O-])=O IDCPFAYURAQKDZ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 4
- JFGCGQJHMUYGLU-UHFFFAOYSA-N 2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethanamine Chemical compound CN(C)CC1=CC=C(CSCCN)O1 JFGCGQJHMUYGLU-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000002026 chloroform extract Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- HPYBQXWXNPCLHV-UHFFFAOYSA-N n-[5-[(1-benzyl-2-oxopyridin-4-yl)methyl]-6-oxo-1h-pyrimidin-2-yl]nitramide Chemical compound O=C1NC(N[N+](=O)[O-])=NC=C1CC1=CC(=O)N(CC=2C=CC=CC=2)C=C1 HPYBQXWXNPCLHV-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 3
- STYQRAZUBODKCA-UHFFFAOYSA-N 1-butyl-2-oxopyridine-4-carbaldehyde Chemical compound CCCCN1C=CC(C=O)=CC1=O STYQRAZUBODKCA-UHFFFAOYSA-N 0.000 description 3
- JEOZNMMOIBLWLV-UHFFFAOYSA-N 2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine Chemical compound CC=1N=CNC=1CSCCN JEOZNMMOIBLWLV-UHFFFAOYSA-N 0.000 description 3
- UHLWQKUEXNRPQC-UHFFFAOYSA-N 2-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethylamino]-5-[(1-methyl-2-oxopyridin-4-yl)methyl]-1h-pyrimidin-6-one Chemical compound N1C=NC(CSCCNC=2NC(=O)C(CC3=CC(=O)N(C)C=C3)=CN=2)=C1C UHLWQKUEXNRPQC-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 3
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
- YSVGRYPDMHTTAY-UHFFFAOYSA-N n-[5-[[1-[2-(dimethylamino)ethyl]-2-oxopyridin-4-yl]methyl]-6-oxo-1h-pyrimidin-2-yl]nitramide Chemical compound O=C1N(CCN(C)C)C=CC(CC=2C(NC(N[N+]([O-])=O)=NC=2)=O)=C1 YSVGRYPDMHTTAY-UHFFFAOYSA-N 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 3
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 2
- DODLXZBQPXDYBG-UHFFFAOYSA-N 2-[2-[[4-[(dimethylamino)methyl]pyridin-2-yl]methylsulfanyl]ethylamino]-5-[(1-methyl-2-oxopyridin-4-yl)methyl]-1h-pyrimidin-6-one Chemical compound CN(C)CC1=CC=NC(CSCCNC=2NC(=O)C(CC3=CC(=O)N(C)C=C3)=CN=2)=C1 DODLXZBQPXDYBG-UHFFFAOYSA-N 0.000 description 2
- FLDCYXOIVORVJI-UHFFFAOYSA-N 2-[[4-[(dimethylamino)methyl]pyridin-2-yl]methylsulfanyl]ethanamine Chemical compound CN(C)CC1=CC=NC(CSCCN)=C1 FLDCYXOIVORVJI-UHFFFAOYSA-N 0.000 description 2
- GTWSSIJFCFOZEK-UHFFFAOYSA-N 3-(1-butyl-2-oxopyridin-4-yl)prop-2-enoic acid Chemical compound CCCCN1C=CC(C=CC(O)=O)=CC1=O GTWSSIJFCFOZEK-UHFFFAOYSA-N 0.000 description 2
- AOADHOGVJRCYRK-UHFFFAOYSA-N 5-[(1-butyl-2-oxopyridin-4-yl)methyl]-2-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethylamino]-1h-pyrimidin-6-one Chemical compound O=C1N(CCCC)C=CC(CC=2C(NC(NCCSCC=3OC(CN(C)C)=CC=3)=NC=2)=O)=C1 AOADHOGVJRCYRK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 2
- 229960000582 mepyramine Drugs 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- UYQGRCCIACNIES-UHFFFAOYSA-N 1-methyl-2-oxopyridine-4-carbaldehyde Chemical compound CN1C=CC(C=O)=CC1=O UYQGRCCIACNIES-UHFFFAOYSA-N 0.000 description 1
- 150000008081 1H-pyrimidin-4-ones Chemical class 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- PUWVODBYTYYTGN-UHFFFAOYSA-N 2-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethylamino]-5-[(1-methyl-2-oxopyridin-4-yl)methyl]-1H-pyrimidin-6-one trihydrochloride Chemical compound Cl.Cl.Cl.CN(C)CC=1OC(=CC1)CSCCNC1=NC=C(C(N1)=O)CC1=CC(N(C=C1)C)=O PUWVODBYTYYTGN-UHFFFAOYSA-N 0.000 description 1
- BJRXZMCJFCAZDL-UHFFFAOYSA-N 2-bromopropanal Chemical compound CC(Br)C=O BJRXZMCJFCAZDL-UHFFFAOYSA-N 0.000 description 1
- MONMFXREYOKQTI-UHFFFAOYSA-N 2-bromopropanoic acid Chemical compound CC(Br)C(O)=O MONMFXREYOKQTI-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- MLGOQTYAPRIUTC-UHFFFAOYSA-N 3-(1-methyl-2-oxopyridin-4-yl)propanoic acid Chemical compound CN1C=CC(CCC(O)=O)=CC1=O MLGOQTYAPRIUTC-UHFFFAOYSA-N 0.000 description 1
- BURAPFFYSNXSIP-UHFFFAOYSA-N 3-[1-[2-(dimethylamino)ethyl]-2-oxopyridin-4-yl]propanoic acid Chemical compound CN(C)CCN1C=CC(CCC(O)=O)=CC1=O BURAPFFYSNXSIP-UHFFFAOYSA-N 0.000 description 1
- VQSXCZMVUMSITD-UHFFFAOYSA-N 3-[3-(piperidin-1-ylmethyl)phenoxy]propan-1-amine Chemical compound NCCCOC1=CC=CC(CN2CCCCC2)=C1 VQSXCZMVUMSITD-UHFFFAOYSA-N 0.000 description 1
- AAEOEVRPMYKMKS-UHFFFAOYSA-N 3-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxypropan-1-amine Chemical compound C1=NC(OCCCN)=CC(CN2CCCCC2)=C1 AAEOEVRPMYKMKS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 1
- QQONABVJKZXMMD-UHFFFAOYSA-N 5-[(1-butyl-2-oxopyridin-4-yl)methyl]-2-[2-[[4-[(dimethylamino)methyl]pyridin-2-yl]methylsulfanyl]ethylamino]-1H-pyrimidin-6-one trihydrochloride Chemical compound Cl.Cl.Cl.O=C1N(CCCC)C=CC(CC=2C(NC(NCCSCC=3N=CC=C(CN(C)C)C=3)=NC=2)=O)=C1 QQONABVJKZXMMD-UHFFFAOYSA-N 0.000 description 1
- SYRRWLSTORRYBD-UHFFFAOYSA-N 5-[(1-butyl-2-oxopyridin-4-yl)methyl]-2-[2-[[4-[(dimethylamino)methyl]pyridin-2-yl]methylsulfanyl]ethylamino]-1h-pyrimidin-6-one Chemical compound O=C1N(CCCC)C=CC(CC=2C(NC(NCCSCC=3N=CC=C(CN(C)C)C=3)=NC=2)=O)=C1 SYRRWLSTORRYBD-UHFFFAOYSA-N 0.000 description 1
- LSQYKHKTLQCCJG-UHFFFAOYSA-N 5-[(1-methyl-2-oxopyridin-4-yl)methyl]-2-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1h-pyrimidin-6-one Chemical compound O=C1N(C)C=CC(CC=2C(NC(NCCCOC=3C=C(CN4CCCCC4)C=CC=3)=NC=2)=O)=C1 LSQYKHKTLQCCJG-UHFFFAOYSA-N 0.000 description 1
- XENOWOQKOFQQNP-UHFFFAOYSA-N 5-[(1-methyl-2-oxopyridin-4-yl)methyl]-2-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1h-pyrimidin-6-one;dihydrochloride Chemical compound Cl.Cl.O=C1N(C)C=CC(CC=2C(NC(NCCCOC=3C=C(CN4CCCCC4)C=CC=3)=NC=2)=O)=C1 XENOWOQKOFQQNP-UHFFFAOYSA-N 0.000 description 1
- VRFDBLVMVIDVCV-UHFFFAOYSA-N 5-[(1-methyl-2-oxopyridin-4-yl)methyl]-2-[3-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxypropylamino]-1h-pyrimidin-6-one Chemical compound O=C1N(C)C=CC(CC=2C(NC(NCCCOC=3N=CC=C(CN4CCCCC4)C=3)=NC=2)=O)=C1 VRFDBLVMVIDVCV-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- YICGFYHFNCLYGZ-SPIKMXEPSA-N OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.O=C1N(C)C=CC(CC=2C(NC(NCCCOC=3N=CC=C(CN4CCCCC4)C=3)=NC=2)=O)=C1 Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.O=C1N(C)C=CC(CC=2C(NC(NCCCOC=3N=CC=C(CN4CCCCC4)C=3)=NC=2)=O)=C1 YICGFYHFNCLYGZ-SPIKMXEPSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940107816 ammonium iodide Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- UBRDUWQQZMMTCA-UHFFFAOYSA-N ethyl 3-(2-methoxypyridin-4-yl)propanoate Chemical compound CCOC(=O)CCC1=CC=NC(OC)=C1 UBRDUWQQZMMTCA-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- VGIVLIHKENZQHQ-UHFFFAOYSA-N n,n,n',n'-tetramethylmethanediamine Chemical compound CN(C)CN(C)C VGIVLIHKENZQHQ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- FEQAUBVIUZJXKN-UHFFFAOYSA-N propan-2-imine;hydrochloride Chemical compound [Cl-].CC(C)=[NH2+] FEQAUBVIUZJXKN-UHFFFAOYSA-N 0.000 description 1
- HHAVHBDPWSUKHZ-UHFFFAOYSA-N propan-2-ol;propan-2-one Chemical compound CC(C)O.CC(C)=O HHAVHBDPWSUKHZ-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- This invention relates to pyrimidinone derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as histamine antagonists.
- Histamine a physiologically active compound endogenous in mammals, exerts its action by interacting with certain sites called receptors.
- receptors One type of receptor is known as a histamine H 1 -receptor (Ash and Schild, Brit. J. Pharmac. Chemother. 27427 (1966)) and the actions of histamine mediated through these receptors are blocked by drugs commonly called “antihistamines" (histamine H 1 -antagonists) a common example of which is mepyramine.
- a second type of histamine receptor is known as the H 2 - receptor (Black et al. Nature 1972, 236, 385). These receptors are not blocked by mepyramine but are blocked by burimamide. Compounds which block these histamine H 2 -receptors are called histamine H 2 - antagonists.
- Histamine H 2 -antagonists are useful in treating disease conditions caused by the biological effects of histamine mediated through H 2 -receptors, for example, as inhibitors of gastric acid secretion, in the treatment of inflammation mediated through histamine H 2 -receptors and as agents which act on the cardiovascular system, for example, as inhibitors of effects of histamine on blood pressure mediated through histamine H 2 -receptors.
- Cimetidine is an example of a histamine H 2 -antagonist. Cimetidine has been shown to be useful in the treatment of duodenal, gastric, recurrent and stomal ulceration, and reflux oesophagitis and in the management of patients who are at high risk from haemorrhage of the upper gastrointestinal tract.
- the compounds of the formulae (A) and (B) are also reported to have histamine H i -antagonist activity.
- histamine H i - and H 2 -receptors In some physiological conditions the biological actions of histamine are mediated through both histamine H i - and H 2 -receptors and blockade of both types of receptors is useful. These conditions include inflammation mediated by histamine, for example skin inflammation, and those hypersensitivity responses due to the action of histamine at H i - and H 2 -receptors, for example allergies.
- the present invention provides a compound of the formula (I):- and pharmaceutically acceptable salts thereof, wherein
- 2-pyridyl optionally substituted by one or more C 1-6 alkyl, C 1-6 alkoxy, halo, amino or hydroxy moieties or substituted in the 4 - position by a group R 3 R 4 N(CH 2 ) m ⁇ wherein R 3 and R 4 are independently hydrogen, C 1-6 alkyl, phenyl(C 1-6 )alkyl, thienyl(C 1-6 )alkyl, furyl(C 1-6 )alkyl, hydroxy(C 1-6 )alkyl, halo(C 1-6 )alkyl or C 3-8 cycloalkyl; or together with the nitrogen atom to which they are attached form a 5-8 membered saturated ring; and m is 1 to 6;
- R 5 and R 6 are independently hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, halo(C 1-6 )alkyl, C 3-6 alkenyl, phenyl(C 1-6 )alkyl, C 3-6 alkynyl, hydroxy(C 1-6 )alkyl, C 1-3 alkoxy(C 1-6 )alkyl, trifluoro(C 1-6 )alkyl, amino(C 1-6 )alkyl, C 1-3 alkylamino(C 1-6 )alkyl or di-(C 1-3 )alkylamino(C 1-6 )alkyl; or R 5 and R 6 together with the nitrogen atom to which they are attached form a 5-8 membered saturated ring;
- phenyl optionally substituted by C 1-6 alkyl, C 1 - s alkoxy, hydroxy, halo, trifluoromethyl, nitro, amino, C 1-6 alkylamino, C 1-6 alkanoylamino, di(C 1-6 )alkylamino or cyano and further optionally substituted in any one of the 3-, 4-, or 5-positions by ⁇ (CH 2 mNR 5 R 6 , ⁇ OCH 2 CH 2 NR 5 R 6 or ⁇ OCH 2 CH 2 CH 2 NR 5 R 6 ;
- A is C 1-5 methylene or ⁇ (CH 2 ) p W(CH 2 ) q where W is oxygen or sulphur and p and q are such that their sum is from 1 to 4;
- R 2 is a pyridone moiety substituted on the nitrogen atom by a group R 7 wherein R 7 is ⁇ (CH 2 ) r NR 8 R 9 wherein R S and R 9 are independently hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, C 3-6 alkenyl, phenyl(C 1-6 )alkyl, C 3-6 alkynyl, hydroxy(C 1-6 )alkyl, C 1-3 alkoxy(C 1-6 )alkyl, trifluoro(C 1-6 )alkyl, amino(C 1-6 )alkyl, C 1-3 alkylamino(C 1-6 )alkyl or di-(C 1-3 )alkylamino(C 1-6 )alkyl; or R S and R 9 together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring, and r is 2 to 6; or R 7 is
- R 7 is C 1 - 4 alkyl optionally substituted by hydroxy, C 1 - 4 alkoxy or phenyl
- Z is hydrogen
- R' is not 2-pyridyl disubstituted, in the 3-position by halo, amino, C 1-4 alkyl or C 3 - 4 alkoxy and in the 5-position by halo, amino or C 1-4 alkyl.
- alkyl and alkoxy mean groups which can be straight or branched.
- preferred alkyl groups are methyl, ethyl, prop-1-yl and prop-2-yl.
- alkoxy groups are methoxy, ethoxy, prop-1-oxy and prop-2-oxy.
- R 1 is 2- or 4-imidazolyl optionally substituted by C 1-6 alkyl, halo, trifluoromethyl or hydroxymethyl; 2-thiazolyl; 2-guanidino-4-thiazolyl optionally substituted by chloro, bromo or C 1-6 alkyl; 2-(5-amino-1,3,4-thiadiazolyl); 3-isothiazolyl optionally substituted by chloro or bromo; 3-(1,2,5)-thiadiazolyl optionally substituted by chloro or bromo; 2-pyridyl optionally substituted by one or more C 1-6 alkyl, C 1-6 alkoxy, halo, amino or hydroxy moieties or substituted in the 4-position by a group R 10 R 11 NCH 2 ⁇ wherein R 10 and R" are independently hydrogen or C 1-6 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidino or piperidino ring; 2-furyl or 2-
- R 1 is 2- or 4-imidazolyl substituted by methyl, bromo or chloro.
- R' is 2-guanidino-4-thiazolyl.
- R 1 is 2-pyridyl substituted by methyl, ethyl, hydroxy, methoxy, ethoxy, chloro, bromo or iodo. Preferably such substituents are in the 3-position, for example 3-bromo and 3-hydroxy.
- R 1 may be 2-pyridyl substituted in the 4-position by a group R 3 R 4 N(CH 2 ) m wherein R 3 , R 4 and m are as hereinbefore defined.
- m is one.
- R 3 and R 4 are independently hydrogen or C 1-6 alkyl or together with the nitrogen atom to which they are attached form a pyrrolidino or piperidino ring.
- R 1 is 2-pyridyl substituted in the 4-position by dimethylaminomethyl, pyrrolidinomethyl or piperidinomethyl.
- R 1 is 2-furanyl or 2-thienyl substituted in the 5-position by a group R 5 R 6 NCH 2 ⁇ wherein R 5 and R 6 are as hereinbefore defined.
- R 5 and R 6 are independently selected from C 1-6 alkyl, trifluoroC 1-6 alkyl for example trifluoroethyl, or R 5 and R 6 together with the nitrogen atom to which they are attached form a piperidino or pyrrolidino ring.
- R 5 is methyl or ethyl.
- R 6 is hydrogen, methyl or ethyl.
- R 5 R 6 NCH 2 ⁇ represents dimethylaminomethyl.
- R 5 N 6 CH 2 ⁇ represents piperidinomethyl.
- R 1 is phenyl either unsubstituted in the 2-position or substituted in that position by C 1-6 alkyl for example methyl, C 1-6 alkoxy for example methoxy, hydroxy, halo such as chloro, trifluoromethyl, amino or cyano.
- the phenyl ring is substituted in the 2-position by methoxy or chloro when there are no further substituents.
- the phenyl ring is unsubstituted in the 2-position when there is a substituent at the 3-, 4- or 5-position.
- such a substituent is a group R 5 R 6 NCH 2 ⁇ wherein R 5 and R S are as hereinbefore defined.
- R 5 is C 1-6 alkyl for example methyl or ethyl, or is trifluoroethyl
- R 6 is hydrogen or C 1-6 alkyl for example methyl or ethyl.
- R 5 R 6 NCH 2 ⁇ represents dimethylaminomethyl.
- R S R 6 NCH 2 - represents piperidinomethyl.
- X is methylene.
- X is oxygen when R 1 is phenyl substituted by a group R 5 R 6 N(CH 2 ) m ⁇ or pyridyl substituted by a group R 5 R 6 N(CH 2 ) m .
- Y is sulphur
- R' is of the sub-formula (i): wherein R 14 and R 15 are independently C 1-6 alkyl or together with the nitrogen atom to which they are attached form a pyrrolidino or piperidino ring; R 16 is 4-pyrid-2-yl, 5-furan-2-yl or 1,3-phenylene.
- R 14 and R 15 are both methyl or together with the nitrogen atom to which they are attached form a piperidino ring.
- R 16 is 5-furan-2-yi or 1,3-phenylene, preferably 5-furan-2-yl.
- R'-X-Y- represents include: 3-methoxypyrid-2-ylethyl, 5-methyl-4-imidazolylmethylthio, and 2-guanidino-4-thiazolylmethylthio, and in particular:
- A is straight or branched alkylene, preferably straight and in particular methylene.
- A is -(CH 2 )pW(CH 2 )q wherein W is oxygen, p is zero and q is one (i.e. ⁇ OCH 2 ⁇ ).
- Other examples of A include methoxymethyl, methylthiomethyl, methoxyethyl and methylthioethyl.
- R 2 is a pyridone ring substituted on the nitrogen by R 7 and may exist in any of the isomeric forms (a)-(f):- 6-oxopyridin-3-yl 2-oxopyridin-3-yl 4-oxopyridin-3-yl 2-oxopyridin-4-yl 6-oxopyridin-2-yl 4-oxopyridin-2-yl
- R 7 is a group R 8 R 9 N(CH 2 ) r ⁇ wherein r, R" and R 9 are as hereinbefore defined. More suitably R 8 is C 1-6 alkyl for example methyl or ethyl, or is trifluoroethyl, and R 9 is hydrogen or C 1 - s alkyl for example methyl or ethyl.
- R 8 R 9 N ⁇ represents piperidino or pyrrolidino.
- r is 2.
- R 7 is dimethylaminoethyl, piperidinoethyl or N-(2,2,2)-trifluoroethyl-N-methyl aminoethyl.
- R 7 is phenyl(C 1 - 6 )alkyl for example benzyl, or phenethyl, or R 7 is C 1-6 alkyl for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or n-pentyl.
- R 7 Particularly favoured values of R 7 are methyl, ethyl, n-butyl, benzyl or dimethylaminoethyl.
- the activity of the compounds of formula (I) as histamine H 2 -antagonists can be demonstrated by their ability to inhibit histamine-stimulated secretion of gastric acid from the lumen-perfused stomachs of rats anaesthetised with urethane, and to reverse histamine-induced inhibition of contractions of the isolated rat uterus. These are actions of histamine which, according to Ash and Schild, Brit. J. Pharmac. Chemother. 27 247 (1966), are not mediated by histamine H I -receptors.
- histamine H 2 -antagonist activity of the compounds can also be demonstrated by the inhibition of histamine-stimulated acid secretion in the Heidenhain Pouch Dog, the inhibition of histamine-induced tachycardia in the isolated guinea pig right atrium and the inhibition of histamine-induced vasodilatation in the anaesthetised cat.
- the compound of Example 2 has an unexpected advantageous effect over analogous compounds of the art, for example Example 7 of EP-A-3677, in that it is more effective after intraduodenal administration to anaesthetised rats.
- the inhibition of histamine-stimulated secretion of gastric acid in rats anaesthetised with urethane was measured after administration of test compounds by intraduodenal injection and intravenous injection.
- the intraduodenal dose required to produce 50% inhibition was only 3 times the intravenous dose required to produce a similar effect
- the intraduodenal dose required was 10 times the intravenous dose.
- the compound of Example 7 of EP-A-3677 required an intraduodenal dose 500 times that of the intravenous dose required to inhibit acid secretion by 50%. Good activity after intraduodenal injection is indicative that there will good activity after oral administration.
- the invention further provides pharmaceutical compositions comprising a compound of formula (I) above or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
- Compounds of formula (I) and their pharmaceutically acceptable salts may be administered orally, parenterally, cutaneously or rectally.
- a syrup formulation will generally consist of a suspension or solution of the compound or salt in a suitable liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
- a suitable liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
- any suitable pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
- Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous carrier or parenterally acceptable oil.
- compositions for administration to the skin include lotions and creams in which the compound of formula (I) or salt thereof is contained in a liquid vehicle.
- a typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as gelatin or cocoa butter or other low melting vegetable waxes or fats.
- the composition is in unit dose form such as a tablet or capsule so that the patient may administer to himself a single dose.
- compositions of the invention will normally be administered to man for the treatment of peptic ulcers and other conditions caused or exacerbated by gastric acidity in the same general manner as that employed for known histamine H 2 -antagonists, due allowance being made in terms of dose levels for the potency of the compound of the present invention relative to known histamine H 2 - antagonists.
- an adult patient will receive an oral dose of between 15 mg and 1500 mg and preferably between 20 mg and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 1.5 mg and 150 mg, and preferably between 5 mg and 20 mg of compound of formula (I) or pharmaceutically acceptable salt thereof calculated as the free base, the composition being administered 1 to 6 times per day.
- This invention further provides a process for preparing a compound of the formula (I) or a pharmaceutically acceptable salt thereof which process comprises:
- Q is nitroamino, C 1-6 alkylthio, benzylthio, chloro or bromo. Of these nitroamino is preferred.
- This process can be performed in the absence of solvent at an elevated temperature, or in the presence of a substantially inert polar solvent for example pyridine, anisole or C 1-6 alkanol at an ambient or elevated temperature.
- a substantially inert polar solvent for example pyridine, anisole or C 1-6 alkanol at an ambient or elevated temperature.
- Q is nitroamino
- the reaction may be carried out in a C 1 - 6 alkanol, for example ethanol or isopropanol, pyridine or anisole at the reflux temperature of the reaction mixture.
- Q is methylthio the reaction may be performed in the absence of solvent at 140°-170°, or the reaction may be performed in refluxing pyridine or anisole.
- examples of the moiety L include chloro, bromo, hydroxy, C 1-6 alkoxy for example methoxy, C 1-6 alkanoyloxy for example acetoxy, arylsulphonyloxy for example 4-methylbenzenesulphonyloxy or C 1-6 alkylsulphonyloxy for example methanesulphonyloxy.
- L is hydroxy in which case the reaction is performed under acidic conditions.
- L is chloro or bromo it is preferable to perform the reaction in the presence of a strong base for example sodium ethoxide in ethanol.
- L is an arylsulphonyloxy or alkylsulphonyloxy group the reaction is preferably performed under mildly basic conditions for example in pyridine solution.
- the reaction between the compounds of the formulae (VI) and (VII) is suitably carried out in the presence of a base.
- suitable bases include alkali metal hydroxides and C 1-4 alkoxides, sodium hydride, and quaternary ammonium hydroxides for example benzyltrimethylammonium hydroxide.
- the base is sodium ethoxide or sodium methoxide.
- the reaction can be carried out in the presence of a solvent the choice of which is not critical to the success of the process provided that it is substantially inert to the reagents and product.
- the solvent is a C 1-4 alkanol, (for example, methanol, ethanol or propanol) or dimethylformamide.
- the reaction can be carried out at moderate temperatures, for example from room temperature to the reflux temperature of the solvent.
- R 17 is methyl or ethyl.
- s and t are both zero so that the group R3R4NCO- (or R 5 R 6 NCO-) is a precursor to the group R 3 R 4 NCH 2 - (or R 5 R 6 NCH 2 ⁇ ).
- the reduction of such a group R 3 R 4 N(CH 2 ) s CO(CH 2 ) t ⁇ may be performed with a hydride for example lithium aluminium hydride.
- R' 8 has a substituent CHO ⁇ (CH 2 ) m-1 ⁇ , which may be converted to a group R 3 R 4 N(CH 2 ) m ⁇ (or R 5 R 6 N(CH 2 ) m ⁇ ) on reaction with an amine under conditions of reductive amination.
- R 18 may have a substituent HO(CH 2 ) m ⁇ which may be converted, for example via Cl(CH 2 ) m ⁇ , to R 3 R 4 N(CH 2 ) m ⁇ (or R 5 R 6 N(CH 2 ) m ⁇ ). Such transformations may be carried out in conventional manner.
- compounds of the formula (I) wherein R 1 is furyl or thienyl either substituted by a R 5 R 6 NCH 2 ⁇ group may be prepared from the corresponding compounds of formula (I) wherein R' is substituted by hydrogen at the relevant position, by reaction with a Mannich reagent, for example formaldehyde and an amine R 5 R 6 NH or salt thereof.
- a Mannich reagent for example formaldehyde and an amine R 5 R 6 NH or salt thereof.
- This reaction may be carried out by treatment of an amine salt with aqueous formaldehyde and a compound of the formula (I) (wherein R' is substituted by hydrogen at the relevant position), or by refluxing an amine salt with paraformaldehyde and a compound of the formula (I) (wherein R' is substituted by hydrogen at the relevant position) in a convenient solvent such as ethanol.
- the Mannich reagent may be a di-(C 1 - 4 alkyl)methylene ammonium salt for example dimethylmethylene ammonium chloride or iodide, or may be a bis di-C 1-4 alkylamino methane, for example bis(dimethylamino)methane.
- Any group in the remainder of the molecule that is capable of reacting with a Mannich reagent may be optionally protected during the reaction, and may be subsequently deprotected in conventional manner.
- the compounds of the formula (IX) may be reduced to form compounds of the formula (1) for example using hydrides.
- Q' is chloro or bromo.
- the reaction is performed under basic conditions, for example the anion of the compound of the formula (X) may be generated, for example using sodium hydride.
- the reaction is performed in a suitable aprotic solvent for example dimethylformamide at a non-extreme temperature for example between 0°C and 100°C, suitably between ambient and 70°C.
- Q 2 is chloro, bromo, arylsulphonyloxy for example 4-methylbenzenesulphonyloxy or C 1 - 6 alkylsulphonyloxy for example methanesulphonyloxy.
- arylsulphonyloxy for example 4-methylbenzenesulphonyloxy or C 1 - 6 alkylsulphonyloxy for example methanesulphonyloxy.
- Such reactions are generally performed in the presence of a base for example triethylamine, an alkoxide or a hydroxide.
- Pharmaceutically acceptable acid addition salts of the compounds of the formula (I) may be prepared from the corresponding base of the compounds of the formula (I) in conventional manner.
- the base may be reacted with an acid in a C 1-4 alkanol, or an ion-exchange resin may be used.
- the salts of the compounds of the formula (I) may be interconverted using ion-exchange resins.
- Non-pharmaceutically acceptable salts are therefore of use as they can be converted to pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable acid addition salts of the compounds of the formula (I) include those formed with hydrochloride, hydrobromic, sulphuric, phosphoric, acetic, citric, maleic, lactic, ascorbic, fumaric, oxalic, methanesulphonic and ethanesulphonic acids.
- the compounds of the formulae (II), (IV) and (XII) are preparable by the methods described in EPA-3677, 4793,13071, 15138, 17679, 17680 and 49173 and GB ⁇ A ⁇ 2030979.
- the compounds of the formula (III) wherein Q is nitroamino may be prepared by the reaction of a compound of the formula (VII) with nitroguanidine.
- the compound of the formula (III) wherein Q is C 1-6 alkylthio or benzylthio may be prepared by the reaction of a compound of the formula (VII) with thiourea followed by alkylation or benzylation.
- the compounds of the formula (VIII) may be prepared in a manner analogous to that described for the preparation of compounds of the formula (I), for example reacting a compound of the formula (III) with an analogue of a compound of the formula (II) wherein R 1 is replaced by R 18 ; provided that R' 8 is suitably protected as necessary.
- the compounds of the formula (IX) wherein R 19 is ⁇ CONH ⁇ may be prepared by the reaction of a compound of the formula (XV) with an activated derivative of a compound of the formula (XVI): wherein R 1 , X and Y are as hereinbefore defined.
- Suitable active derivatives are acyl halides, anhydrides and activated esters.
- the aldehydes of the formula (XIV) may be prepared for example by reacting a compound of the formula (XVII): wherein R 1 is as hereinbefore defined, with a protected bromopropionaldehyde (for example protected as a cyclic acetal) and deprotecting.
- the acid of the formula (XVI) and derivatives thereof may be prepared in similar manner for example by reacting a compound of the formula (XVII) with a protected bromopropionic acid and if necessary deprotecting and/or converting to the desired activated acid derivative.
- the compounds of the formulae (V), (XI) and (XIII) may be prepared for example by methods analogous to that described for the reaction of compounds of the formulae (II) and (III), that is reacting a compound of the formula (III) with HSCH 2 CH 2 NH 2 , Q 1 CH 2 CH 2 CH 2 NH 2 , or Q 2 CH 2 CH 2 NH 2 , wherein the nature of the groups Q 1 and Q 2 is such that the desired reaction occurs.
- the compounds of the formula (VII) wherein Z is hydrogen may be prepared for example by the reaction of a compound of the formula (XVIII):- wherein A, R 2 and R 17 are as hereinbefore defined, with a formylating agent, for example a C 1-6 alkyl formate such as ethyl formate, in the presence of a strong base.
- a formylating agent for example a C 1-6 alkyl formate such as ethyl formate
- sodium hydride in 1,2-dimethoxyethane or tetrahydrofuran may be used.
- sodium in ether may be used.
- the compounds of the formula (VII) wherein Z is hydrogen or C 1 - 6 alkyl may be prepared in conventional manner, such as adaptation of the disclosure of British Specification 1582527.
- the compounds of the formula (VI) may be prepared by the reaction of a compound of the formula (II) with a compound of the formula (XIX):- wherein T is a leaving group such as methylthio.
- any groups may be optionally protected, if appropriate, in conventional manner.
- suitable amino-protecting groups for the processes described herein include tertiarybutyloxycarbonyl removable by trifluoroacetic acid, benzyloxycarbonyl removable by hydrogenolysis or hydrobromic acid, and phthaloyl removable by hydrazine.
- Suitable hydroxy protecting groups include benzyloxycarbonyl, methoxymethyl, methylthiomethyl, tetrahydropyranyl, benzyl, C 1-6 alkyl for example methyl, and acyl for example formyl or acetyl.
- N-Methyl-4-formyl-2-pyridone * (30.17 g), monoethyl malonate (38.15 g), pyridine (150 ml) and piperidine (3 ml) were stirred under reflux for 6) hours.
- the reaction mixture was evaporated under reduced pressure to afford a residue which was crystallised from aqueous isopropanol to give ethyl ⁇ -(N-methyl-2-oxo-4-pyridyl)acrylate as a pale yellow solid (18.44 g), m.p. 126-7°C.
- a solution of sodium (2.31 g) in methanol (50 ml) was prepared. To this was added, with stirring, nitroguanidine (9.28 g) (containing 25% w/w water) and methanol (10 mI). The mixture was stirred under reflux for one hour and a semi-solution, semi-suspension of ethyl a-formyl-p-(N-methyl-2-oxo-4-pyridyl)propionate (15.87 g) in methanol (60 ml) was added over the period of one hour. The reaction mixture was refluxed for 20 hours, and evaporated under reduced pressure to afford an oil.
- N-n-Butyl-4-(ethylenedioxymethyl)-2-pyridone (94.49 g) and 3% hydrochloric acid (50 ml of concentrated hydrochloric acid made up to 570 ml) were heated on a steam bath for 30 minutes. The solution was allowed to cool overnight and taken to pH 8 with potassium carbonate solution. The reaction mixture was extracted into chloroform (6 x 200 ml), and the combined chloroform extracts were washed with water (2 x 50 ml), dried over MgS0 4 and evaporated under reduced pressure to afford an oil. This oil was washed with petroleum ether (40°-60°) and on cooling N-n-butyl-4-formyl-2-pyridone was obtained as a solid (64.37 g), m.p. 36-40°C.
- N-n-Butyl-4-formyl-2-pyridone (68.71 g), malonic acid (39.90 g), pyridine (225 ml) and piperidine (4.5 ml) were stirred under reflux for 6 hours.
- the reaction mixture was evaporated under reduced pressure to afford an oil, to which was added water and a small amount of ammonia ('880 solution) to aid dissolution.
- the solution was taken to pH 4 with acetic acid, the solvent volume was diminished under reduced pressure and acetone added to precipitate a solid.
- a pharmaceutical composition for oral administration is prepared by mixing together the product of Example 2 (55% wt/wt), dibasic calcium phosphate dihydrate (20%) and colouring agent (0.5%), adding a concentrated solution of polyvinylpyrrolidine (4%), granulating, drying and screening the dried granules: adding microcrystalline cellulose (8%), maize starch (8%), sodium glycollate (4%) and magnesium stearate (0.5%) to the granules and compressing into tablets containing 100 mg, 150 mg or 200 mg of the free base of the product of Example 2.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Dc Digital Transmission (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Luminescent Compositions (AREA)
- Pyridine Compounds (AREA)
- Lubricants (AREA)
- Optical Filters (AREA)
- Saccharide Compounds (AREA)
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT83307257T ATE50574T1 (de) | 1982-12-03 | 1983-11-29 | Aminopyrimidinone als histamin-h2-antagonisten. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8234615 | 1982-12-03 | ||
GB8234615 | 1982-12-03 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0117345A2 EP0117345A2 (de) | 1984-09-05 |
EP0117345A3 EP0117345A3 (en) | 1985-09-11 |
EP0117345B1 true EP0117345B1 (de) | 1990-02-28 |
Family
ID=10534737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP83307257A Expired - Lifetime EP0117345B1 (de) | 1982-12-03 | 1983-11-29 | Aminopyrimidinone als Histamin-H2-Antagonisten |
Country Status (18)
Country | Link |
---|---|
US (1) | US4540699A (de) |
EP (1) | EP0117345B1 (de) |
JP (1) | JPS59110692A (de) |
KR (1) | KR840006995A (de) |
AT (1) | ATE50574T1 (de) |
AU (1) | AU2175083A (de) |
CA (1) | CA1208215A (de) |
DE (1) | DE3381243D1 (de) |
DK (1) | DK552283A (de) |
ES (1) | ES527739A0 (de) |
FI (1) | FI834410A (de) |
GR (1) | GR79023B (de) |
IL (1) | IL70341A0 (de) |
JO (1) | JO1275B1 (de) |
NO (1) | NO834438L (de) |
PT (1) | PT77757B (de) |
ZA (1) | ZA838987B (de) |
ZW (1) | ZW26083A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8421427D0 (en) * | 1984-08-23 | 1984-09-26 | Smith Kline French Lab | Chemical compounds |
DE3532880A1 (de) * | 1985-09-14 | 1987-03-26 | Basf Ag | 1,4-disubstituierte pyrazolderivate |
JPH0613486B2 (ja) * | 1987-12-07 | 1994-02-23 | 株式会社池田模範堂 | ピリミドン誘導体及びその医薬的に許容される塩 |
FR2686084B1 (fr) * | 1992-01-10 | 1995-12-22 | Bioprojet Soc Civ | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. |
USRE37303E1 (en) * | 1992-01-10 | 2001-07-31 | Institut National Del La Sante Et De La Recherche Medicale | Imidazole compounds and their therapeutic applications |
US20220242824A1 (en) * | 2019-05-14 | 2022-08-04 | Conopco, Inc., D/B/A Unilever | Cosmetic composition |
US11826453B2 (en) | 2019-05-14 | 2023-11-28 | Conopco, Inc. | Hair care composition comprising piroctone olamine |
WO2022034121A1 (en) | 2020-08-11 | 2022-02-17 | Université De Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3980781A (en) * | 1966-03-31 | 1976-09-14 | Imperial Chemical Industries Limited | Fungicidal composition and method containing 2-amino-pyrimidines |
GB1419994A (en) * | 1973-05-03 | 1976-01-07 | Smith Kline French Lab | Heterocyclicalkylaminotheterocyclic compounds methods for their preparation and compositions comprising them |
EP0017680B1 (de) * | 1979-04-11 | 1982-04-21 | Smith Kline & French Laboratories Limited | Pyrimidon-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen |
-
1983
- 1983-11-26 JO JO19831275A patent/JO1275B1/en active
- 1983-11-28 AU AU21750/83A patent/AU2175083A/en not_active Abandoned
- 1983-11-28 IL IL70341A patent/IL70341A0/xx unknown
- 1983-11-29 DE DE8383307257T patent/DE3381243D1/de not_active Expired - Lifetime
- 1983-11-29 US US06/556,209 patent/US4540699A/en not_active Expired - Fee Related
- 1983-11-29 AT AT83307257T patent/ATE50574T1/de active
- 1983-11-29 EP EP83307257A patent/EP0117345B1/de not_active Expired - Lifetime
- 1983-11-30 ZW ZW260/83A patent/ZW26083A1/xx unknown
- 1983-11-30 GR GR73113A patent/GR79023B/el unknown
- 1983-11-30 PT PT77757A patent/PT77757B/pt unknown
- 1983-12-01 DK DK552283A patent/DK552283A/da not_active Application Discontinuation
- 1983-12-01 FI FI834410A patent/FI834410A/fi not_active Application Discontinuation
- 1983-12-02 NO NO834438A patent/NO834438L/no unknown
- 1983-12-02 ES ES527739A patent/ES527739A0/es active Granted
- 1983-12-02 CA CA000442461A patent/CA1208215A/en not_active Expired
- 1983-12-02 KR KR1019830005714A patent/KR840006995A/ko not_active Application Discontinuation
- 1983-12-02 JP JP58229020A patent/JPS59110692A/ja active Pending
- 1983-12-02 ZA ZA838987A patent/ZA838987B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DK552283A (da) | 1984-06-04 |
GR79023B (de) | 1984-10-02 |
PT77757A (en) | 1983-12-01 |
ES8504792A1 (es) | 1985-04-16 |
ES527739A0 (es) | 1985-04-16 |
AU2175083A (en) | 1984-06-07 |
ATE50574T1 (de) | 1990-03-15 |
US4540699A (en) | 1985-09-10 |
DE3381243D1 (de) | 1990-04-05 |
NO834438L (no) | 1984-06-04 |
CA1208215A (en) | 1986-07-22 |
DK552283D0 (da) | 1983-12-01 |
JO1275B1 (en) | 1985-04-20 |
JPS59110692A (ja) | 1984-06-26 |
PT77757B (en) | 1986-04-16 |
EP0117345A3 (en) | 1985-09-11 |
ZW26083A1 (en) | 1985-04-17 |
ZA838987B (en) | 1985-02-27 |
FI834410A0 (fi) | 1983-12-01 |
KR840006995A (ko) | 1984-12-04 |
FI834410A (fi) | 1984-06-04 |
IL70341A0 (en) | 1984-02-29 |
EP0117345A2 (de) | 1984-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0050458B1 (de) | 2-Guanidino-4-heteroarylthiazole und diese enthaltende Arzneimittel | |
EP0068834B1 (de) | Pyrimidinonderivate und diese enthaltende pharmazeutische Zusammenstellungen | |
EP0117345B1 (de) | Aminopyrimidinone als Histamin-H2-Antagonisten | |
AU702609B2 (en) | Pyridylthio compounds for controlling helicobacter bacteria | |
US4377576A (en) | 5-(Heterocyclic amino-propionyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones | |
US4694008A (en) | Chemical compounds | |
EP0051371B1 (de) | Therapeutische Zusammenstellungen von Imidazol-Pyridinen | |
EP0134096B1 (de) | Aminopyrimidinon-Derivate als Histamin-H2-Antagonisten | |
EP0039989B1 (de) | Pyrimidonderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
US4935424A (en) | 4 or 5-(substituted piperazinylalkyl)-2-aminothiazoles as antipsychotic agents | |
US4567176A (en) | 4H-Imidazol-4-ones and their pharmaceutical use | |
US4738969A (en) | Substituted aminopyridones and aminoquinolones having histamine H2 -receptor blocking activity | |
JPS6330903B2 (de) | ||
US4808589A (en) | Pyrimidone derivatives | |
US3378564A (en) | Certain pyridyl tetrazole derivatives | |
US4468399A (en) | 2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyrimidones | |
CA1206151A (en) | Pyrimidone anti-ulcer agents | |
EP0081955B1 (de) | Benzo-Kondensierte heterocyclische Derivate | |
US4571398A (en) | Cytosine derivatives having histamine H2 -antagonist activity | |
CA1166253A (en) | 4-amino-6-(pyridinyl)-3(2h)-pyridazinones, preparation and cardiotonic use | |
EP0172968A1 (de) | Aminothiadiazinderivate als Histamin-H2-Antagonisten | |
JPS5936674A (ja) | N−置換グアニジノチアゾ−ル誘導体およびその製造法 | |
KR820001993B1 (ko) | 히스타민h₂수용체 길항작용을 가진 니트로 화합물의 제조방법 | |
EP0206623B1 (de) | Pyridinderivate | |
GB2137197A (en) | Thicro-thiazole h2 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19831205 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19880628 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19900228 Ref country code: LI Effective date: 19900228 Ref country code: CH Effective date: 19900228 Ref country code: AT Effective date: 19900228 |
|
REF | Corresponds to: |
Ref document number: 50574 Country of ref document: AT Date of ref document: 19900315 Kind code of ref document: T |
|
ITF | It: translation for a ep patent filed | ||
REF | Corresponds to: |
Ref document number: 3381243 Country of ref document: DE Date of ref document: 19900405 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19901129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19901130 Ref country code: BE Effective date: 19901130 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
BERE | Be: lapsed |
Owner name: SMITH KLINE & FRENCH LABORATORIES LTD Effective date: 19901130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19910601 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19910731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19910801 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |